Hiddo J Lambers Heerspink
Overview
Explore the profile of Hiddo J Lambers Heerspink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
110
Citations
5307
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu H, Greasley P, Lambers Heerspink H, Ambery P, Ahlstrom C, Hamren B, et al.
Br J Pharmacol
. 2024 Aug;
181(22):4693-4707.
PMID: 39159936
Background And Purpose: Endothelin-1 (ET-1) receptor A (ETA) antagonists reduce proteinuria and prevent renal outcomes in chronic kidney disease (CKD) patients, but their utility has been limited because of associated...
2.
Smeijer J, Kohan D, Rossing P, Correa-Rotter R, Liew A, Tang S, et al.
Cardiovasc Diabetol
. 2023 Sep;
22(1):251.
PMID: 37716952
Background: Insulin resistance (IR) is a pathophysiologic hallmark of type 2 diabetes and associated with the presence of chronic kidney disease (CKD). Experimental studies suggest that endothelin-1 increases IR. We...
3.
Charytan D, Mahaffey K, Jardine M, Cannon C, Neal B, Lambers Heerspink H, et al.
BMJ Open Diabetes Res Care
. 2023 Jun;
11(3).
PMID: 37311602
Introduction: Relationships between glycemic-lowering effects of sodium glucose co-transporter 2 inhibitors and impact on kidney and cardiovascular outcomes are uncertain. Research Design And Methods: We analyzed 4395 individuals with prebaseline...
4.
Schechter M, Cohen C, Yanuv I, Rozenberg A, Chodick G, Bodegard J, et al.
Cardiovasc Diabetol
. 2022 Jun;
21(1):104.
PMID: 35689214
Background: Type-2 diabetes (T2D), chronic kidney disease, and heart failure (HF) share epidemiological and pathophysiological features. Although their prevalence was described, there is limited contemporary, high-resolution, epidemiological data regarding the...
5.
Beernink J, Oosterwijk M, Khunti K, Gupta P, Patel P, van Boven J, et al.
Diabetes Care
. 2021 Apr;
44(6):1419-1425.
PMID: 33893164
Objective: To assess adherence to the three main drug classes in real-world patients with type 2 diabetes using biochemical urine testing, and to determine the association of nonadherence with baseline...
6.
Jardine M, Zhou Z, Lambers Heerspink H, Hockham C, Li Q, Agarwal R, et al.
Clin J Am Soc Nephrol
. 2021 Feb;
16(3):384-395.
PMID: 33619120
Background And Objectives: The kidney protective effects of renin-angiotensin system inhibitors are greater in people with higher levels of albuminuria at treatment initiation. Whether this applies to sodium-glucose cotransporter 2...
7.
Sokooti S, Kieneker L, de Borst M, Kobold A, Kootstra-Ros J, Gloerich J, et al.
J Clin Med
. 2020 Sep;
9(9).
PMID: 32957570
C-peptide measurement may represent a better index of pancreatic β-cell function compared to insulin. While insulin is mainly cleared by liver, C-peptide is mainly metabolized by kidneys. The aim of...
8.
Reijrink M, De Boer S, Spoor D, Lefrandt J, Lambers Heerspink H, Boellaard R, et al.
Atherosclerosis
. 2019 Oct;
290:87-93.
PMID: 31604171
Background And Aims: Type 2 diabetes mellitus (T2DM) is commonly associated with abdominal obesity, predominantly with high visceral adipose tissue (VAT), and is accompanied by premature atherosclerosis. However, the association...
9.
van den Brand J, Dijkstra T, Wetzels J, Stengel B, Metzger M, Blankestijn P, et al.
PLoS One
. 2019 May;
14(5):e0216559.
PMID: 31071186
Rationale & Objective: Early prediction of chronic kidney disease (CKD) progression to end-stage kidney disease (ESKD) currently use Cox models including baseline estimated glomerular filtration rate (eGFR) only. Alternative approaches...
10.
Keyzer C, van Breda G, Vervloet M, De Jong M, Laverman G, Hemmelder M, et al.
J Am Soc Nephrol
. 2016 Nov;
28(4):1296-1305.
PMID: 27856633
Reduction of residual albuminuria during single-agent renin-angiotensin-aldosterone blockade is accompanied by improved cardiorenal outcomes in CKD. We studied the individual and combined effects of the vitamin D receptor activator paricalcitol...